Full Press Release Details
BridgeBio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).
BBIO
BridgeBio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Key Takeaway: BridgeBio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Price reaction · baseline $76.3 (2025-12-19 close) · clean, no other BBIO news in the window
day 0 close · peak
+1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis